Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Novel targets for potential therapeutic use in Diabetes mellitus
Future targets are a promising prospect to overcome the limitation of conventional and
current approaches by providing secure and effective treatment without compromising …
current approaches by providing secure and effective treatment without compromising …
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
The α-cell in diabetes mellitus
Findings from the past 10 years have placed the glucagon-secreting pancreatic α-cell centre
stage in the development of diabetes mellitus, a disease affecting almost one in every ten …
stage in the development of diabetes mellitus, a disease affecting almost one in every ten …
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
In a healthy person, the kidney filters nearly 200 g of glucose per day, almost all of which is
reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium …
reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium …
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Introduction: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder associated
with high cardiovascular (CV) risk. Some of the therapeutic strategies are contraindicated in …
with high cardiovascular (CV) risk. Some of the therapeutic strategies are contraindicated in …
[HTML][HTML] Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes
Patients with type 2 diabetes (T2DM) have a significantly higher risk of develo**
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …
Recent advances in improving oral drug bioavailability by cocrystals
Introduction: Oral drug delivery is the most favored route of drug administration. However,
poor oral bioavailability is one of the leading reasons for insufficient clinical efficacy …
poor oral bioavailability is one of the leading reasons for insufficient clinical efficacy …
Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis
Objective (s): Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor,
possesses verified anti-inflammatory and anti-oxidative stress effects against diabetic …
possesses verified anti-inflammatory and anti-oxidative stress effects against diabetic …
Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: a systematic review and network meta‐analysis
X Hu, Y Yang, X Hu, X Jia, H Liu… - Diabetes, Obesity and …, 2022 - Wiley Online Library
Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes …
(SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes …
Natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors
W Blaschek - Planta medica, 2017 - thieme-connect.com
Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon
as well as by regulation of glucose absorption, gluconeogenesis, biosynthesis and …
as well as by regulation of glucose absorption, gluconeogenesis, biosynthesis and …